The follow -up study indicated that Multikine treatment
resulted in a substantial increase in the survival of patients. Improved local regional control of the tumor is considered by many
surgeons and oncologists to be an important measurement of the success of a
head + neck cancer drug. Such statements are subject to risks and uncertainties which
could cause actual results to differ materially from those projected.

ulcers neck

syndrome dental

Multikine is a patented immunotherapeutic agent consisting of a mixture of
naturally occurring cytokines, including interleukins, interferons, chemokines
and colony-stimulating factors , currently being developed for treatment of
cancer.
Oral cancer can spread quickly.

conditions lip

, CEL-SCI Corporation
(Amex: CVM) announces positive results from a long-term follow-up study of
head + neck cancer patients treated with its drug Multikine(R) in a Phase II
clinical trial.
We are very excited by these results and hope to repeat these very promising
results in our Phase III clinical trial. government support, have shown protection against a number of diseases in
animal tests and are being tested against diseases associated with bio-defense
and avian flu.

conditions caries

Both survival and local regional control of the
tumor are stated endpoints in CEL-SCI's planned Phase III clinical trial . Other products, in the pre-clinical stage and funded with
U. They found that
saliva from the patients with Sjogren's has both increased amounts of proteins
related to inflammation and a decreased amount of proteins produced by
salivary glands.

digestive ulcers

David Wong's laboratory at the School of Dentistry at UCLA have
discovered that seven RNAs, molecules that carry information in cells, when
found in saliva are very useful for oral cancer detection.

bruxism joint

signup syndrome

Today, at the 35th
Annual Meeting of the American Association for Dental Research, Wong's
research team is reporting for the first time that they have developed a
standardized "Saliva RNA Test for Oral Cancer" ready for clinical usage. Future studies are planned to determine whether these protein
levels could be useful in diagnosing Sjogren's syndrome.

abscess symptoms

The results
of the Phase II trial follow-up study showed that the Multikine -treated
patients had substantially increased survival rates and achieved a higher rate
of 2-year local regional control as compared to the survival and the 2-year
local regional control rates published in the scientific literature (39
clinical trials between 1987 and 2004 in a similar population of head + neck
cancer patients).S.
Currently, the early detection of oral cancer depends on a thorough oral
cancer examination, usually by a dentist or other qualified health care
provider , for possible signs and symptoms of this disease.

ulcers toothaches

The majority of oral cancers are diagnosed in
late stages, which accounts for the high death rates. The saliva oral
cancer RNA signature has been tested in over 300 saliva samples from oral
cancer patients and healthy people, and the signature is always present in
higher levels in the saliva of oral cancer patients than in saliva from
healthy people , with an overall accuracy rate of about 85%.

toothaches dentistry

CEL-SCI has recently completed the submission of all
of the additional information the FDA requested and awaits the FDA's response. Patients suffer from constant dryness of the mouth and eyes,
as well as many other systemic problems.

caries bruxism

"
CEL-SCI received the go-ahead for its proposed Phase III trial from the
Canadian drug regulatory authority in August 2005.
CEL-SCI Corporation is developing new immune system based treatments for
cancer and infectious diseases.

The First Clinical Test for Saliva-Based Oral Cancer Detection: Ready Now!

ORLANDO, Fla.

joint mouth

The Phase II study, which used the same Multikine treatment protocol as
proposed for the Phase III trial, included advanced primary head + neck cancer
patients who were scheduled for their first cancer treatment.
The median follow-up period for the patients was 3.

neck lip

Results
from this study were published in a leading cancer publication, the Journal of
Clinical Oncology (Timar et al, JCO, 23(15): May 2005). At this time, CEL-SCI cannot provide the detailed results
of this long-term follow-up study of Multikine treatment as the data are
currently being prepared for publication. Following each of these meetings the FDA requested that additional
information be provided . Factors
that could cause or contribute to such differences include, an inability to
duplicate the clinical results demonstrated in clinical studies, timely
development of any potential products that can be shown to be safe and
effective, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in CEL-SCI
Corporation's SEC filings, including but not limited to its report on Form 10-
K/A for the year ended September 30, 2004. Only half of those
diagnosed with the disease will survive more than five years. This is the first
standardized saliva-based test for clinical oral cancer detection and will
have enormous clinical value in reducing the mortality and morbidity for oral
cancer patients, as well as improving their quality of life .

joint dentistry

In this recent study, the scientists
analyzed saliva from patients with and without Sjogren's syndrome to find out
whether the amounts and types of salivary proteins differed.

signup emedicine

The same proposed Phase III
trial was submitted to and discussed with the United States Food and Drug
Administration (FDA) in two separate End of Phase II meetings held during
2005.

When used in this report , the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking
statements. Scientists are
working on technologies and biomarkers for the early detection of oral cancer.

bruxism cavity

The disease kills approximately one person every hour.
The next important step is to turn these scientific findings into clinical
tests that can be used for early oral cancer detection.

Conditions and diseases related to Dentistry

periodontal joint

In addition,
Multikine treatment also improved local regional control of the patients'
tumors. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine is
cleared to enter Phase III clinical trials with advanced primary head and neck
cancer patients.

periodontal lip

2 years., Oral cancer is the 6th most common
cancer in men and the 14th most common cancer in women. In the US, oral cancer
will be diagnosed in an estimated 30,000 Americans this year and will cause
more than 8,000 deaths.
Saliva, an easy-to-obtain and non-invasive body fluid, has recently been shown
to harbor highly informative biomarkers for oral cancer detection.

periodontal emedicine

VIENNA, Va. It is
therefore extremely important to detect oral cancer as early as possible, when
it can be treated more successfully , thus enhancing the rate of survival.

conditions symptoms

The Multikine
treatment was administered for 3 weeks prior to the standard treatment for
head + neck cancer, surgery or surgery plus radiation/chemotherapy .
Head and neck cancer is an aggressive cancer that affects about 500,000
people per annum worldwide.

signup burning

About 92% of those cases are outside of the U. The Company undertakes no
obligation to publicly release the result of any revision to these forward-
looking statements which may be made to reflect the events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events. Scientists
in Dr.

abscess emedicine

,
and about two thirds of all cases present with advanced disease. However, if the
cancer is detected early, there is an 80 to 90% chance for survival. The
"Saliva RNA Test" has been tested in 100 oral cancer and healthy people, and
it has been confirmed that four saliva oral cancer RNA biomarkers are highly
accurate in detecting oral cancer, at around 82%.
In a related study, further illustrating the importance of saliva as a
diagnostic tool , scientists at the National Institute of Dental and
Craniofacial Research (NIDCR), one of the Federal Government's National
Institutes of Health (NIH), have studied the protein profile in the saliva of
patients with Sjogren's syndrome, an autoimmune disorder in which the immune
system cells attack the saliva- and tear-producing glands, causing them to
become inflamed.

toothaches burning

diseases bruxism

Multikine Treatment Increases Survival in Cancer Patients

Maximilian de Clara, President of CEL-SCI, states, "These results suggest
that Multikine has the potential to bring much needed benefit to patients with
head + neck cancer, a disease that has significant morbidity and mortality and
for which there has been little improvement in therapy over the last 20 years.S.